Radiotherapy is used in> 50% of patients with cancer, both for curative and palliative
purposes. Radiotherapy uses ionizing radiation to target and kill tumour tissue, but normal …

In recent years, conventional treatments including surgery, chemotherapy and radiotherapy
have been the main approaches in tumour therapy. Cancer immunotherapy is a new …

Cancer immunotherapy by educating or stimulating patients' own immune systems to attack
cancer cells has demonstrated promising therapeutic responses in the clinic. However …

A better knowledge of the complex interactions between cancer cells and the immune
system has led to novel immunotherapy approaches. Treatment with selective anti-PD1, anti …

Resistance to cancer therapy remains a major challenge in clinical oncology. Although the
initial treatment phase is often successful, eventual resistance, characterized by tumour …

Research into the immunological processes implicated in cancer has yielded a basis for the
range of immunotherapies that are now considered the fourth pillar of cancer treatment …

Background Selecting the appropriate patients to receive immunotherapy (IO) remains a
challenge due to the lack of optimal biomarkers. The presence of liver metastases has been …

Immune checkpoint inhibition (ICI) immunotherapy has revolutionized the approach to
metastatic non-small-cell lung cancer (NSCLC). In particular, antibodies blocking the …

Radiotherapy (RT), the major anti-cancer modality for more than half of cancer patients after
diagnosis, has the advantage of local tumor control with relatively less systematic side …

Rationale: Radiotherapy combined with immunotherapy has revealed promising outcomes
in both preclinical studies and ongoing clinical trials. Targeted radionuclide therapy (TRT) is …